These findings were confirmed in a separate study utilizing several EGFR mutant NSCLC cell lines, which showed increased FGFR1 and FGF2 mRNA and protein levels in response to gefitinib exposure [59]. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.